Pros and cons of including C reactive protein (CRP) in future clinical trials in inflammatory bowel disease
| In favour of including CRP in clinical trials | Against including CRP in clinical trials |
|---|---|
| (1) Allows objective selection of patients with active disease | (1) Carries risk of restricting drugs to patient with high CRP |
| (2) Higher likelihood of response and lower placebo response rates | (2) Risk of more restrictive FDA label |
| (3) Objective marker for follow up effect of treatment | (3) Yet unclear which CRP cut off value is best |